POAI Predictive Oncology Inc.: Company Value to Revenue

Official company branding of Predictive Oncology Corp (POAI)

How can a unique bio-sample archive for cancer therapy selection be effectively monetized? The EV-to-revenue ratio on the precise GURU.Markets chart for Predictive Oncology (POAI), where the value is fixed at 30000.00, demonstrates the asset's dynamics. Stability is ensured by the non-cyclical nature of long-term AI development funding, while the business's sustainability is supported by digital modeling that reduces the number of physical chemical tests.

Predictive Oncology Inc (POAI): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 12/12/2025

POAI (Predictive Oncology Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
Initial company analysis:Predictive Oncology Corp
Manufactured products of Predictive Oncology Inc.

This indicator measures the enterprise value—business market value plus net debt—comparing this total capital to annual revenue to eliminate distortions caused by leverage. By analyzing the current price-to-sales valuation of Predictive Oncology (POAI), an investor can determine the extent to which the market is overvaluing the potential of the company's AI platform for tumor response modeling and its unique biosample database, which creates high barriers to entry for competitors.

Competitor analysis

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|TKNO - EV/Sales Multiple|Monogram Technologies Inc (MGRM) - Enterprise Value-to-Revenue Ratio|STSS - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio InfuSystem Holdings, Inc.|Enterprise Value-to-Revenue Multiple Utah Medical Products UTMD|EV/Sales Multiple KRMD|Total Company Value-to-Revenue Ratio Nyxoah, S.A.|Microbot Medical Inc - Company Value to Revenue|Total Company Value-to-Revenue Ratio Pro-Dex Inc. (PDEX)|Zentek - EV/Sales Multiple|Elutia (ELUT) - Company Value to Revenue|Milestone Scientific Inc (MLSS) - Enterprise Value-to-Revenue Ratio|NXGL - Total Company Value-to-Revenue Ratio|Company Value to Revenue RVP|Harvard Bioscience, Inc. (HBIO) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple FEMY|EV/Sales Multiple Meihua Medical Technologies (MHUA)|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple